Latest Earnings Results: Q2 '26
Estimated EPS
-$0.12
Reported EPS
-$0.11
Surprise
+7.65%
Estimated Rev
$92.34M
Reported Rev
$99.31M
Surprise
+7.56%
• Reported GAAP EPS of -$0.11 up 66.67% YoY • Reported revenue of $198.63M up 231.31% YoY • Iovance Biotherapeutics is reviewing its previously issued 2026 total revenue guidance of $350 million to $370 million based on strong second-quarter sales and current demand trends, with an update expected later.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.09 | -- | -- | N/A |
Q2 '26 | -$0.12 | -$0.11 | 7.65% | BEAT |
Q1 '26 | -$0.15 | -$0.19 | -23.68% | MISSED |
Q4 '25 | -$0.17 | -$0.18 | -2.90% | MISSED |
Q3 '25 | -$0.26 | -$0.25 | 2.98% | BEAT |